Ellen Bjurgert - Coloplast A/S VP Relations
| CLPBF Stock | USD 121.15 0.15 0.12% |
Insider
Ellen Bjurgert is VP Relations of Coloplast AS
| Phone | 45 49 11 11 11 |
| Web | https://www.coloplast.com |
Coloplast A/S Management Efficiency
The company has return on total asset (ROA) of 0.1714 % which means that it generated a profit of $0.1714 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7507 %, meaning that it generated $0.7507 on every $100 dollars invested by stockholders. Coloplast A/S's management efficiency ratios could be used to measure how well Coloplast A/S manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 12 records | INSIDER Age | ||
| Erez BenZvi | GlucoTrack | 46 | |
| Esq CPA | GlucoTrack | 59 | |
| Robert Hayes | Sharps Technology | 57 | |
| Eyal MD | Microbot Medical | 59 | |
| David BA | GlucoTrack | 59 | |
| Rachel Vaknin | Microbot Medical | 45 | |
| Alan Blackman | Sharps Technology | 75 | |
| Andrew CPA | Sharps Technology | 68 | |
| Steven MD | Sharps Technology | 62 | |
| Pr DSc | Microbot Medical | 72 | |
| MScEE MBA | GlucoTrack | 70 | |
| Barry Berler | Sharps Technology | 70 | |
Management Performance
| Return On Equity | 0.75 | |||
| Return On Asset | 0.17 |
Coloplast A/S Leadership Team
Elected by the shareholders, the Coloplast A/S's board of directors comprises two types of representatives: Coloplast A/S inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Coloplast. The board's role is to monitor Coloplast A/S's management team and ensure that shareholders' interests are well served. Coloplast A/S's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Coloplast A/S's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ellen Bjurgert, VP Relations | ||
| Allan Rasmussen, Executive VP of Global Operations | ||
| Alain Morvan, Senior Vice President Sales Europe | ||
| Thomas Barfod, Director, Employee Representative | ||
| Nicolai Andersen, Senior Vice President Wound Care | ||
| Anders LonningSkovgaard, CFO, Executive Vice President Member of the Executive Management | ||
| Kristian Villumsen, Executive VP of Chronic Care | ||
| Paul Marcun, Senior Vice President Emerging Markets | ||
| Dorthe Ronnau, VP Culture | ||
| Dennis Kaysen, Director Communications |
Coloplast Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Coloplast A/S a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.75 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 28.84 B | |||
| Shares Outstanding | 194.31 M | |||
| Shares Owned By Insiders | 35.00 % | |||
| Shares Owned By Institutions | 25.53 % | |||
| Price To Earning | 37.47 X | |||
| Price To Book | 22.60 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Coloplast Pink Sheet
Coloplast A/S financial ratios help investors to determine whether Coloplast Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Coloplast with respect to the benefits of owning Coloplast A/S security.